⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460224 | 0.94 | CYP3A4 (0.41) | — | |
| SCHEMBL19134142 | 0.92 | CYP3A4 (0.40) | — | |
| Hydrochloric Acid SCHEMBL3733909 | 0.92 | CYP3A4 (0.40) | — | |
| SCHEMBL23963172 | 0.92 | CYP3A4 (0.40) | — | |
| SCHEMBL21210714 | 0.92 | CYP3A4 (0.40) | — | |
| SCHEMBL5544928 | 0.78 | — | — | |
| SCHEMBL21742813 | 0.78 | MEN1 (0.37) | — | |
| SCHEMBL1016848 | 0.77 | — | — | |
| SCHEMBL5537391 | 0.75 | ALDH1A1 (0.33) | — | |
| SCHEMBL22407911 | 0.74 | CYP3A4 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753935-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2020-12-23 | — | — | EP | claimed |
| US-9567324-B2 | Substituted nicotinamide derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2017-02-14 | — | — | US | claimed |
| EP-3080084-A1 | SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2016-10-19 | — | — | EP | claimed |
| US-20160194311-A1 | SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. | 2016-07-07 | — | — | US | claimed |
| US-9266869-B2 | Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2016-02-23 | — | — | US | claimed |
| US-20150166518-A1 | SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. | 2015-06-18 | — | — | US | claimed |
| US-20150166521-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. | 2015-06-18 | — | — | US | claimed |
| WO-2015089220-A1 | SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| EP-3753935-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3080105-B1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3080084-B1 | SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2018-06-13 | — | — | EP | disclosed |
| CN-205992546-U | Electric energy storage device housing material and electric energy storage device | 昭和电工包装株式会社 | 2017-03-01 | — | — | CN | disclosed |
| US-9567324-B2 | Substituted nicotinamide derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-3080084-A1 | SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-7211680-B2 | Vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-01 | — | — | US | disclosed |
| US-20050080058-A1 | New vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments | SCHERING AKTIENGESELLSCHAFT PATENTS (DE) | 2005-04-14 | — | — | US | disclosed |
| US-6642218-B2 | (5Z,7E,22E)-(1S,3R,24R)-25-(5-Propyloxazol-2-yl)-26,27-cyclo -9,10-secocholesta-5,7,10(19), 22-tetraene-1,3,24-triol for treatment of diseases characterized by hyperproliferation and deficient cell differentiation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-04 | — | — | US | disclosed |
| US-6613920-B1 | 25-(5-propylimidazol-2-yl)-26,27-cyclo-9, 10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol; antagonizes the action of calcitriol in HL 60 cells; hyperprolifierative diseases of the skin, tumor diseases and precancerous stages | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-02 | — | — | US | disclosed |
| US-6600058-B1 | The invention concerns new vitamin D derivatives of general formula (I) a process for their production, their use for production of medicaments, and intermediate products used in the process. treating a patient for hyperprolifierative | SCHERING AKTIENGELLSCHAFT (DE) | 2003-07-29 | — | — | US | disclosed |
| US-20020049344-A1 | NEW VITAMIN D DERIVATIVES WITH CARBO-OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-25 | — | — | US | disclosed |